Loading stock data…
SNSE
$21.08+0.08 (+0.38%)
Pre-Market$21.89+0.81 (+3.84%)· Last close May 13
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sensei Biotherapeutics, Inc. in the Healthcare sector is trading at $21.08. Wall Street consensus targets $50.00 (1 analysts), implying a +137.2% move over the next 12 months. The stock is currently 43% below its 52-week high of $36.76, remaining 37.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 6 is oversold, raising the odds of a near-term bounce. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +137.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 6) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$21.08
Potential Downside
0%
Whystock Fair Value$21.08
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$50.00+137.2%
Range$50.00 – $50.00
Fundamentals
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selec...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$42.59M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-113.41%
Volume
Today's trading volume
39,185
Recent News
Sensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street Analysts
Sensei Biotherapeutics Inc. (NASDAQ:SNSE) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 30, Sensei Biotherapeutics shifted its focus following the acquisition of Faeth Therapeutics and a concurrent $200 million private placement. The company’s lead program is now PIKTOR, an all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. This new […]
Sensei to ditch its lead candidate and cut workforce amidst strategic review
The Boston-based biotech is axing Phase II plans for its only clinical-stage asset, in a bid to maximise shareholder value.